Earnings Summary

Novavax, Inc.’s revenue jumped 60.85% since last year same period to $357.4Mn in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -51.35% fall in its revenue since last 3-months.

Novavax, Inc.’s net profit jumped 78.46% since last year same period to $-182.25Mn in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -8.09% fall in its net profits since last 3-months.

Novavax, Inc.’s net profit margin jumped 86.61% since last year same period to -50.99% in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -122.16% fall in its net profit margins since last 3-months.

Novavax, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.14 - a -172.61% fall from last quarter’s estimates.

Novavax, Inc.’s earning per share (EPS) estimates for the current year stand at -1.14.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Novavax, Inc.’s return on assets (ROA) stands at -0.17.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Novavax, Inc.’s return on equity (ROE) stands at -8.98.